Meet the 2025 Winner - Mark T. Gladwin, MD
Dr. Mark Gladwin is the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the University of Maryland School of Medicine and Vice President for Medical Affairs at the University of Maryland, Baltimore. He received his BS/MD degree from the University of Miami six-year Honors Program in Medical Education, and completed his internship and chief residency in Internal Medicine at the Oregon Health Sciences University in Portland, Oregon, followed by a Critical Care Medicine fellowship at the NIH and a Pulmonary Fellowship at the University of Washington in Seattle. He returned for post-doctoral research fellowships at the NIH in cell and molecular biology, and later served as the Chief of the Pulmonary and Vascular Medicine Branch within the NHLBI. In 2008, Dr. Gladwin was recruited to the University of Pittsburgh to serve as Chief of the Division of Pulmonary, Allergy and Critical Care Medicine and the inaugural Director of the Vascular Medicine Institute, and in 2015 became Chair of the Department of Medicine at the University of Pittsburgh.
Dr. Gladwin has received the US Public Health Service Achievement Award, the NIH Director’s Award for Mentoring, the NIH Clinical Center Director’s Award for Science, and the NIH Merit Award. He also received the Recognition Award for Scientific Accomplishments from the American Thoracic Society, and was named an American Heart Association Distinguished Scientist.
Dr. Gladwin maintains an active research group and is currently PI of three R01 awards and a UH3/UG3 clinical trial. He has published more than 500 manuscripts since 1996, which have had a significant impact on the fields of vascular and nitric oxide biology. Dr. Gladwin’s research has led to four scientific discoveries: 1) the nitrite anion is a circulating storage pool for NO bioactivity that regulates hypoxic vasodilation and the cellular resilience to low oxygen and ischemia; 2) a novel physiological function for hemoglobin and globin-family members as electronically- and allosterically-regulated nitrite reductase; 3) the characterization of a novel mechanism of disease, hemolysis-associated endothelial dysfunction; and 4) the mechanistic, clinical, and epidemiological description of a human disease syndrome, hemolysis-associated pulmonary hypertension. Dr. Gladwin has a long history of leadership of translational projects and programs, and has served as PI on major multicenter phase II clinical trials, including the DeNOVO trial of NO therapy for acute pain crisis in patients with sickle cell disease, the Walk-PHASST trial of sildenafil for pulmonary hypertension secondary to sickle cell disease, STERIO-SCD, and the current SCD-CARRE blood transfusion trial. Most recently, his laboratory has pioneered the use of recombinant neuroglobin and heme-based molecules as antidotes for CO poisoning, and this work resulted in the formation of a company, Globin Solutions.
Description
The Pulmonary Circulation Leadership Award is given annually in the Appreciation of Decades of Leadership and Devoted Service to the Pulmonary Circulation Research Community.